Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ATYR vs OBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATYR Captures Overall Composite Edge (34.3 SELL vs 42.9 HOLD), While OBIO Leads 3–2 on Growth & Valuation Pillars

ATYR Overall Winner 6-Pillar Tally: ATYR 2 – 3 OBIO (1 Tie) Matrix Metrics: ATYR 4 – 4 OBIO

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (34.3/100 SELL vs. 42.9/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. ATYR trades at $4.96 (N/M Forward P/E, 0.0% operating margin) versus OBIO at $7.07 (N/M Forward P/E, -195.4% operating margin).

  • Composite vs. Pillar Nuance: While OBIO currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -195.4% operating margin) and revenue trajectory (+0.0% vs. -89.4% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ATYR vs OBIO
ATYR NASDAQ Head-to-Head Winner
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.96
-5.34% 1D
Market Cap $15.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -9.67β · 13806% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (391.4% over 20 days), RSI 58
RSI-14: 57.6 · SMA20: $4.36 · SMA50: $1.92
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.07
-0.7% 1D
Market Cap $570.6M
TTM Revenue $31M
Forward P/E N/M
Beta / 30D Vol 1.15β · 80% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 15.0 Fund 40.0 Flow 62.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.8% over 20 days), RSI 68
RSI-14: 68.1 · SMA20: $5.99 · SMA50: $5.94

6-Pillar Scorecard Institutional Category Breakdown (ATYR 2 – 3 OBIO)

Columns: Metric · ATYR · OBIO
1. Valuation Multiples OBIO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 18.6x
2. Growth & Scale OBIO
Revenue Growth (YoY) +0.0% -89.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $31M
Market Cap $15.6M $570.6M
3. Profitability & Quality ATYR
Gross Margin N/A 99.6%
Operating Margin 0.0% -195.4%
Net Profit Margin 0.0% -182.5%
Return on Equity (ROE) -93.7% -182.3%
4. Balance Sheet & Cash Flow ATYR
Cash Generation (TTM) N/A -$64M
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.9M Net Cash $9.0M Net Debt (4.72x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OBIO
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile 154.5% (36th %ile) 70.8% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ATYR (4) vs OBIO (4)
Institutional Metric ATYR OBIO Criterion Row Edge
Market Capitalization
Scale
$15.6M $570.6M Larger Scale OBIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -89.4% Higher Growth ATYR
Operating Margin (TTM)
Profitability
0.0% -195.4% Higher Margin ATYR
Net Profit Margin
Profitability
0.0% -182.5% Higher Margin ATYR
Return on Equity (ROE)
Capital Efficiency
-93.7% -182.3% Higher ROE ATYR
52-Week Range Position
Momentum
62% ($0–$8) 90% ($3–$7) Stronger Trend OBIO
Beta / 30D Volatility
Risk Regime
-9.67β · 13806% Vol 1.15β · 80% Vol Lower Realized Risk OBIO
Unified Institutional Score
Composite Signal
34.3 / 100 (SELL) 42.9 / 100 (HOLD) Higher Composite OBIO
Trailing 12M Revenue (USD)
Operating Scale
N/A $31M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 99.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 18.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($4.9M Net Cash) -$64M ($9.0M Net Debt (4.72x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATYR +2763.63 pp
ATYR: +2788.76% · OBIO: +25.13%
3M Horizon ATYR +803.54 pp
ATYR: +830.93% · OBIO: +27.39%
6M Horizon ATYR +850.17 pp
ATYR: +926.92% · OBIO: +76.75%
1Y Horizon ATYR +479.26 pp
ATYR: +558.7% · OBIO: +79.44%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ATYR Revenue OBIO Revenue ATYR Op. Margin OBIO Op. Margin Margin Leader
FY2019 $0M N/A -5445.0% N/A ATYR
FY2020 $10M N/A -152.2% N/A ATYR
FY2022 $10M $0M -446.8% -924.3% ATYR
FY2023 $0M $0M -15557.8% -1866.2% OBIO
FY2024 $0M $0M -28899.6% -2437.5% OBIO
FY2025 $0M $30M -40856.3% -154.7% OBIO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ATYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 154.5%
IV Percentile 36th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OBIO BREAKOUT
33d in phase · OBV ACCUMULATION
Current IV 70.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ATYR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $570.6M market capitalization and -195.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ATYR vs OBIO Key Questions & Quantitative Answers

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (34.3/100 SELL vs. 42.9/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. ATYR trades at $4.96 (N/M Forward P/E, 0.0% operating margin) versus OBIO at $7.07 (N/M Forward P/E, -195.4% operating margin). Composite vs. Pillar Nuance: While OBIO currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -195.4% operating margin) and revenue trajectory (+0.0% vs. -89.4% YoY).

OBIO leads the Growth & Scale pillar: ATYR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with OBIO at -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin). Across the 6-period historical trajectory (FY2019 to FY2025), ATYR cumulative revenue shifted +0.0% while OBIO shifted N/A. In operating R&D and SG&A reinvestment, ATYR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OBIO.

OBIO screens cheaper on headline valuation multiples. ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATYR (-93.7% ROE) versus OBIO (-182.3% ROE) capital efficiency.

In options market volatility and institutional positioning, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.67β · 13806% Vol realized risk). By comparison, OBIO carries 70.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.15β · 80% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.